Attendee search 

Assay development is a complex process than can rapidly become a bottleneck in both basic research and drug discovery laboratories. BioAuxilium Research provides customized services in biochemical, cell-based and biomarker assay development across a number of therapeutic areas using various high-throughput technology platforms. BioAuxilium also offers preclinical sample testing services using no-wash immunoassay technologies. 

Regardless of the scope of your project, we can design and develop a robust, sensitive and reproducible assay that will meet your requirements and expectations.

Specialties

Custom assay development, Biomarker detection and quantification, Biochemical and cell-based assays, Immunogenicity testing, Expert consulting, Preclinical sample testing (ligand binding assays), ELISA conversion to no-wash immunoassays

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a chronic, life-threatening disease that affects millions of people worldwide. In the United States, 30,000 new cases are estimated every year with half of those cases diagnosed in young children. Type 1 diabetes is an autoimmune disease in which the patient’s immune system goes awry and attacks and destroys the pancreatic beta cells. Beta cells are responsible for regulating blood sugar (glucose) levels by producing precise amounts of the essential hormone insulin.

The discovery of injectable insulin in the 1920s changed T1D from a uniformly fatal disease with a life expectancy of months to one that could be carefully managed for decades through multiple daily blood glucose measurements and insulin injections. However, insulin injections are not a cure and patients face a lifetime of difficult disease management and serious complications including kidney failure, blindness and nerve damage. Despite nearly a century passing since the discovery of insulin, insulin injection remains the only treatment available to patients.

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes.

Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

AlfaGene is an innovative biotechnology company that uses its own novel proprietary cutting edge adult stem cell technology to create the only stem cell and non-transformed primary epithelial cell derived model of each segment of the entire gastrointestinal (GI) tract.

Gastrointestinal diseases affect millions of people, young and old all across the globe and cause heavy economical consequences for nations around the world. In the United States alone, GI diseases consume over $22 billion health care dollars annually with treatments that are usually not curative but just symptom relieving.  GI stem and epithelial cells are the main cellular component affected in the malignant transformation, inflammation, immune responses (e.g. autoimmune response), and disease of the GI tract, including:

• colorectal cancer (CRC)

• ulcerative colitis (UC)

• Crohn's Disease (CD)

• irritable bowel syndrome (IBS)

• short bowel syndrome

• gastroesophageal reflux disease (GERD) and Barrett’s esophagitis.

Trillium Medical Center is a South Florida based medical facility specializing in Internal Medicine.  The center has facilities to diagnose and treat Internal Medical problems.  By providing our patients with state of the art Preventative, Acute, and Chronic treatment options we are able to help patients lose weight safely, maintain healthy diet regimens and life styles, and ensure their health conditions are monitored on a regular basis. 

By extending our capabilities to provide 24 hour/365 Day access to patient's health records, each patient can gain access to their important and vital medical information no matter where they travel or which physician they visit, even if it is not at our center.  

We also offer a variety of "In House" tertiary services including an in house Med Spa complete with Esthetic services including Botox, Juvederm, Microdermabrasion and other wellness treatments like Weight Management and Nutrition training.

About HackensackUMC Mountainside Focused on medical excellence and community service for more than a century Patient focused, community oriented, conveniently located and equipped with technology that rivals the nation’s most prestigious healthcare systems, HackensackUMC Mountainside offers a comprehensive and growing array of services delivered by caring and highly skilled medical professionals. We’re proud of the therapeutic and administrative upgrades we have made. We’re the convenient, friendly community hospital that delivers the quality care, medical excellence and technology on which you can depend. HackensackUMC Mountainside has been serving Montclair and its surrounding New Jersey communities since 1891. The physicians, nurses and volunteers who are a part of the Mountainside family are also your friends and neighbors. We're your community, your hospital and your team, working hard on your behalf. Continuously moving forward Never content with the status quo, we continue to add services, staff, programs and technology to benefit our patients and our communities. From our state-of-the-art emergency center with its Fast Track program to our holistic mind-body women's program to our comprehensive cancer center and a weight-loss surgery program recognized nationally as a Center of Excellence, HackensackUMC Mountainside is the right choice in the greater Montclair area. In 1891, the beginning of a great tradition Margaret Jane Merewether Power was a preacher’s daughter who came from England to Montclair in 1874 with her husband. One summer day in 1890 she encountered a child who had fallen from a third-story window. Upset that there was no nearby healthcare facility where the child could be helped, she called on other women in her social circle to find a solution – marking the birth of HackensackUMC Mountainside. By 1891, a three-story cottage belonging to widow Eliza Sheridan had been purchased. Dr. John J.H. Love was named the first President of the Medical and Surgical Staff, and HackensackUMC Mountainside officially began its mission of “caring for, curing and nurturing the sick and injured.” Today, 119 years later, HackensackUMC Mountainside is still carrying out that mission. With 365 beds and 820,000 square feet in total, HackensackUMC Mountainside has come a long way. But some things never change. The compassion and commitment to the community felt by Mrs. Power continues to this day. A member of the Montclair Health Systems, LLC On February 1, Montclair Health System, LLC, a joint venture of LHP Hospital Group, Inc. and Hackensack University Medical Center, initiated the state government process required to acquire Mountainside Hospital.

HackensackUMC Mountainside is unique among New Jersey hospitals. While many others are seeking new owners because their futures remain uncertain, one of the nation’s most prestigious hospitals, HackensackUMC and LHP Hospital Group, Inc. one of the nation’s most innovative capital and healthcare management firms are choosing to affiliate with HackensackUMC Mountainside because of its strength and stability.

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

• CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
• Curie Cancer, a component of Institut Curie focused on cancers
• ICM, the Brain and Spine Institute dedicated to CNS diseases
• Pasteur MI, the infectious diseases division of the Institut Pasteur
• Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

Specialties

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

GLOBAL CARE Initiative GLOBAL CARE Initiative is a consortium of 5 French leading research institutes focused on infectious diseases (The institut Pasteur), oncology (The institut Curie), lymphoma (CALYM), vision and audition diseases (Voir et Entendre) and CNS (The brain and spine institute). Industry sectors All Therapeutics Area CNS-Neurology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Oncology
Ophthalmology
Rare Disease
Your innovative solution

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

Which problem are you solving ?

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Target market segments

Basic research / Preclinical research / Clinical

Key value proposition

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

The Massachusetts Medical Device Development Center (M2D2) is a lifeline for the state’s smaller medical device companies, offering inventors and executives easy, affordable, and coordinated access to world-class researchers and resources at the Lowell and Worcester campuses of the University of Massachusetts.

Learn more.